Additional analyses from the SCORED trial further highlight sotagliflozin's benefits among patients with type 2 diabetes and chronic kidney disease, regardless of cardiovascular disease presence.
Updated findings from SCORED presented by Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, at the American College of Cardiology’s (ACC) 70th Scientific Session offered new insights on the benefits of sotagliflozin in patients with type 2 diabetes and chronic kidney disease (CKD).
Specifically, the treatment resulted in significantly reduced cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with and without cardiovascular disease (CVD).
Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor. SGLT1 functions as the primary transporter for absorption of glucose and galactose in the gastrointestinal tract, and SGLT2 is expressed in the kidney and reabsorbs 90% of filtered glucose.
In the SCORED trial, a total of 10,584 stable outpatients with diabetes and CKD were randomized to the treatment or placebo for a median of 16 months. In the current analysis, researchers assessed those with (n = 5144) and without (n = 5440) CVD at baseline to determine the drug’s effect.
Investigators found:
Overall, a 26% reduction was seen in the treatment arm with regard to composite of total CV deaths, hospitalizations for heart failure, and urgent heart failure visits, with a very early, significant benefit seen at around 3 months.
Major adverse cardiac event benefits were seen regardless of prior coronary, cerebral, or peripheral artery disease and absence of established cardiovascular disease.
Researchers hypothesize the positive findings could be due to the drug’s unique additional SGLT1 inhibition, in contrast with other SGLT2 inhibitor trials, although “the evolution of SGLT2 inhibitors in heart failure management has been nothing short of remarkable,” Bhatt said.
Adverse events reported in SCORED included urinary tract infections, diarrhea, volume depletion and bone fractures, among others. Notably, researchers saw a significant increase in diarrhea among those taking sotagliflozin, most likely reflecting the SGLT1 inhibition in the gut, Bhatt explained.
However, proportions of serious adverse events were similar between the treatment and control arms while adverse events generally did not lead to treatment discontinuation.
As SCORED was stopped early due to COVID-19, its shortened duration limited statistical power with regard to significant reductions in CV death. This early endpoint also “limited the magnitude of absolute risk reductions in MACE [major adverse cardiovascular events],” Bhatt said.
Sotagliflozin is not yet FDA approved although it has been authorized for type 1 diabetes by the European Medical Agency. Lexicon Pharmaceuticals has filed for FDA approval in the United States.
“I hope it gets approved. I think it might be the best-in-class,” Bhatt said. “It has the heart failure benefits that other SGLT2 inhibitors have, I think that’s a class effect…I think starting it early in patients without contraindication is the right thing to do.”
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More